Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Net Margin (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Net Margin for 16 consecutive years, with 86.15% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 1546.0% year-over-year to 86.15%, compared with a TTM value of 78.72% through Sep 2025, up 685.0%, and an annual FY2024 reading of 104.58%, down 6067.0% over the prior year.
  • Net Margin was 86.15% for Q3 2025 at China Pharma Holdings, down from 51.51% in the prior quarter.
  • Across five years, Net Margin topped out at 24.28% in Q1 2023 and bottomed at 155.48% in Q2 2024.
  • Average Net Margin over 5 years is 61.34%, with a median of 54.02% recorded in 2023.
  • The sharpest move saw Net Margin plummeted -10147bps in 2024, then skyrocketed 10397bps in 2025.
  • Year by year, Net Margin stood at 33.94% in 2021, then dropped by -28bps to 43.28% in 2022, then plummeted by -32bps to 57.32% in 2023, then plummeted by -88bps to 107.98% in 2024, then rose by 20bps to 86.15% in 2025.
  • Business Quant data shows Net Margin for CPHI at 86.15% in Q3 2025, 51.51% in Q2 2025, and 69.13% in Q1 2025.